首页 > 最新文献

European journal of rheumatology and inflammation最新文献

英文 中文
Four commonly prescribed non-steroidal anti-inflammatory drugs for rheumatoid arthritis. 类风湿性关节炎常用的四种非甾体类抗炎药。
E C Huskisson

A four-way single-blind crossover study was used to compare the efficacy and tolerance of four non-steroidal anti-inflammatory drugs. In addition, pain intensity was compared during the day, at night, at rest, on walking, in the most painful joint, and with the patients most painful activity. Ninety-six patients with rheumatoid arthritis took single daily doses of controlled release naproxen (N), diclofenac S.R. (D), indomethacin S.R. (I) and standard piroxicam (P). The greatest changes from baseline after treatment were seen in those patients with the highest initial pain measurement scores. Assessments of pain in the morning, in the most painful joint and the most painful activity were more discriminating than those at noon or at rest. Of the treatments, 'N' and 'P' were the most effective in reducing pain, with statistically significant differences from baseline. 'I' was the most effective in reducing morning stiffness. Adverse experiences were generally mild, occurring more frequently on 'I' than on other treatments.

采用四路单盲交叉研究比较四种非甾体抗炎药的疗效和耐受性。此外,还比较了白天、夜间、休息、行走、最痛关节和患者最痛活动时的疼痛强度。96例类风湿关节炎患者服用单次每日剂量的控释萘普生(N)、双氯芬酸S.R. (D)、吲哚美辛S.R. (I)和标准吡罗西康(P)。治疗后与基线相比变化最大的是那些初始疼痛测量评分最高的患者。早晨、最痛的关节和最痛的活动的疼痛评估比中午或休息时的疼痛评估更具辨别性。在治疗方法中,“N”和“P”在减轻疼痛方面最有效,与基线相比有统计学上的显著差异。“I”是缓解晨僵最有效的方法。不良经历通常是轻微的,“I”治疗比其他治疗更频繁。
{"title":"Four commonly prescribed non-steroidal anti-inflammatory drugs for rheumatoid arthritis.","authors":"E C Huskisson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A four-way single-blind crossover study was used to compare the efficacy and tolerance of four non-steroidal anti-inflammatory drugs. In addition, pain intensity was compared during the day, at night, at rest, on walking, in the most painful joint, and with the patients most painful activity. Ninety-six patients with rheumatoid arthritis took single daily doses of controlled release naproxen (N), diclofenac S.R. (D), indomethacin S.R. (I) and standard piroxicam (P). The greatest changes from baseline after treatment were seen in those patients with the highest initial pain measurement scores. Assessments of pain in the morning, in the most painful joint and the most painful activity were more discriminating than those at noon or at rest. Of the treatments, 'N' and 'P' were the most effective in reducing pain, with statistically significant differences from baseline. 'I' was the most effective in reducing morning stiffness. Adverse experiences were generally mild, occurring more frequently on 'I' than on other treatments.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"11 2","pages":"8-12"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12537678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gastroscopic evaluation of the effects of nabumetone on the gastrointestinal mucosa of rheumatic patients. 纳布美酮对风湿病患者胃肠道黏膜影响的胃镜评价。
G Bianchi Porro, M Petrillo, S Ardizzone, I Caruso, F Montone

Endoscopic studies with nabumetone have consistently shown a lower incidence of gastro-duodenal erosive lesions than comparable non-steroidal anti-inflammatory drugs (NSAIDs) including naproxen and ibuprofen.

纳布美酮的内镜研究一致显示,胃-十二指肠糜烂病变的发生率低于类似的非甾体抗炎药(NSAIDs),包括萘普生和布洛芬。
{"title":"Gastroscopic evaluation of the effects of nabumetone on the gastrointestinal mucosa of rheumatic patients.","authors":"G Bianchi Porro,&nbsp;M Petrillo,&nbsp;S Ardizzone,&nbsp;I Caruso,&nbsp;F Montone","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Endoscopic studies with nabumetone have consistently shown a lower incidence of gastro-duodenal erosive lesions than comparable non-steroidal anti-inflammatory drugs (NSAIDs) including naproxen and ibuprofen.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"11 3","pages":"38-42"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12537683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Concerns and choices in general practice. 一般实践中的关注点和选择。
J D Mulder

Osteoarthritis is a common problem in general practice and a major indication for NSAIDs. Many patients with osteoarthritis are elderly and therefore particularly at risk from adverse reactions. Co-morbidity and co-prescription may lead to drug interactions. For these reasons, safe NSAIDs are the first choice for this disease.

骨关节炎是一个常见的问题,在一般做法和主要适应症的非甾体抗炎药。许多骨关节炎患者是老年人,因此特别容易发生不良反应。共同发病和共同处方可能导致药物相互作用。由于这些原因,安全的非甾体抗炎药是治疗这种疾病的首选。
{"title":"Concerns and choices in general practice.","authors":"J D Mulder","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Osteoarthritis is a common problem in general practice and a major indication for NSAIDs. Many patients with osteoarthritis are elderly and therefore particularly at risk from adverse reactions. Co-morbidity and co-prescription may lead to drug interactions. For these reasons, safe NSAIDs are the first choice for this disease.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"11 3","pages":"3-6"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12537682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and improved safety--a new anti-arthritic agent. 一种新型抗关节炎药物,疗效好,安全性高。
M Irani

Long term studies with nabumetone have confirmed that it is an effective NSAID, comparable to other agents including aspirin and naproxen. Large scale post-marketing studies have shown high response rates and good tolerance.

对那布美酮的长期研究证实,它是一种有效的非甾体抗炎药,与阿司匹林和萘普生等其他药物相当。大规模的上市后研究表明,反应率高,耐受性好。
{"title":"Efficacy and improved safety--a new anti-arthritic agent.","authors":"M Irani","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Long term studies with nabumetone have confirmed that it is an effective NSAID, comparable to other agents including aspirin and naproxen. Large scale post-marketing studies have shown high response rates and good tolerance.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"11 3","pages":"43-9"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12537684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A comparative study of nabumetone and indomethacin in ankylosing spondylitis. 纳布美酮与吲哚美辛治疗强直性脊柱炎的比较研究。
T G Palferman, M Webley

Forty-two patients with ankylosing spondylitis were entered into a double-blind study to compare treatment with indomethacin and a new non-steroidal anti-inflammatory drug, nabumetone. Clinical, laboratory and side-effect profiles were measured over a three month period. Both drugs were effective in relieving pain and morning stiffness, indomethacin was better in alleviating general stiffness, nabumetone resulted in less side-effects. Objective measurements of spinal movements revealed no difference between the two drugs. Nabumetone, available as Relifex, appears as effective as indomethacin in relieving the symptoms of ankylosing spondylitis and is possibly better tolerated.

42名强直性脊柱炎患者进入了一项双盲研究,比较吲哚美辛和一种新的非甾体抗炎药纳布美酮的治疗效果。在三个月的时间里测量了临床、实验室和副作用的概况。两种药物均能有效缓解疼痛和晨僵,吲哚美辛缓解全身僵硬效果较好,纳布美酮副作用较小。脊髓运动的客观测量显示两种药物之间没有差异。在缓解强直性脊柱炎的症状方面,纳布美酮与吲哚美辛一样有效,而且耐受性可能更好。
{"title":"A comparative study of nabumetone and indomethacin in ankylosing spondylitis.","authors":"T G Palferman,&nbsp;M Webley","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Forty-two patients with ankylosing spondylitis were entered into a double-blind study to compare treatment with indomethacin and a new non-steroidal anti-inflammatory drug, nabumetone. Clinical, laboratory and side-effect profiles were measured over a three month period. Both drugs were effective in relieving pain and morning stiffness, indomethacin was better in alleviating general stiffness, nabumetone resulted in less side-effects. Objective measurements of spinal movements revealed no difference between the two drugs. Nabumetone, available as Relifex, appears as effective as indomethacin in relieving the symptoms of ankylosing spondylitis and is possibly better tolerated.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"11 2","pages":"23-9"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12538625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The case for preventive rheumatology. 预防风湿病学的案例。
D L Scott, T D Spector
{"title":"The case for preventive rheumatology.","authors":"D L Scott,&nbsp;T D Spector","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"11 2","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12538622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic activity, clinical and gastric tolerance of 20mg daily dose of droxicam in comparison with piroxicam in patients with degenerative joint disease. 对退行性关节疾病患者每日剂量20mg的droxicam与piroxicam的治疗活性、临床和胃耐受进行比较
E Schüetz, J Sánchez, J García-Barbal, J F Sarti, C Reuter, F J Harrison

The efficacy and safety of droxicam were compared with piroxicam in a pilot study in twenty patients with degenerative joint disease. After a one week washout period a baseline gastroscopy was carried out. Treatment during the following 4 weeks was randomised to droxicam or piroxicam. Safety and tolerance parameters were monitored at weekly intervals. Pain was evaluated with two visual analogue scales (VAS) (patient and investigator). Affected joints, articular index (AI), patient's status and a daily living activities questionnaire were also evaluated. Another gastroscopy was carried out at the end of the treatment period. Droxicam and piroxicam relieved all symptoms significantly without statistically significant clinical differences. Both groups showed no drug related side effects in the laboratory values. In the gastroscopic examinations two patients of the droxicam group and four of piroxicam group had minor gastric erosions after four weeks of treatment without any accompanying clinical symptoms.

在20例退行性关节疾病患者的初步研究中,比较了droxicam与piroxicam的疗效和安全性。经过一周的洗脱期后,进行基线胃镜检查。在接下来的4周治疗中,随机分配到氯昔康或吡罗西康。每周监测一次安全性和公差参数。采用两种视觉模拟量表(VAS)对疼痛进行评估(患者和研究者)。受影响的关节、关节指数(AI)、患者状态和日常生活活动问卷也进行了评估。在治疗期结束时进行另一次胃镜检查。Droxicam与piroxicam均显著缓解上述症状,临床差异无统计学意义。两组均未出现与药物相关的副作用。在胃镜检查中,治疗4周后,droxicam组2例,piroxicam组4例出现轻微胃糜烂,无临床症状。
{"title":"Therapeutic activity, clinical and gastric tolerance of 20mg daily dose of droxicam in comparison with piroxicam in patients with degenerative joint disease.","authors":"E Schüetz,&nbsp;J Sánchez,&nbsp;J García-Barbal,&nbsp;J F Sarti,&nbsp;C Reuter,&nbsp;F J Harrison","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The efficacy and safety of droxicam were compared with piroxicam in a pilot study in twenty patients with degenerative joint disease. After a one week washout period a baseline gastroscopy was carried out. Treatment during the following 4 weeks was randomised to droxicam or piroxicam. Safety and tolerance parameters were monitored at weekly intervals. Pain was evaluated with two visual analogue scales (VAS) (patient and investigator). Affected joints, articular index (AI), patient's status and a daily living activities questionnaire were also evaluated. Another gastroscopy was carried out at the end of the treatment period. Droxicam and piroxicam relieved all symptoms significantly without statistically significant clinical differences. Both groups showed no drug related side effects in the laboratory values. In the gastroscopic examinations two patients of the droxicam group and four of piroxicam group had minor gastric erosions after four weeks of treatment without any accompanying clinical symptoms.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"11 4","pages":"21-8"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12539348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Droxicam: a pharmacological and clinical review of a new NSAID. Droxicam:一种新的非甾体抗炎药的药理学和临床回顾。
F Jané, A Rodríguez de la Serna

Droxicam acts by inhibition of PGE2 varies. Although it belongs to the oxicam family, it is characterised by being a pro-drug of piroxicam, the molecule undergoing conversion by hydrolysis once dissolved in the digestive tract. This allows us to suppose in principle that, there being less contact between the active drug (piroxicam) and the gastric mucosa, the side effects in the said mucosa would be slight. The studies which have already been performed in healthy volunteers and in patients with osteoarthritis and rheumatoid arthritis, to evaluate the efficacy and the tolerance of droxicam in patients suffering from such clearly inflammatory processes demonstrate an analgesic potential and anti-inflammatory effects which become noticeable after two weeks of treatment, and the drug is well-tolerated.

Droxicam通过抑制PGE2而起作用。虽然它属于奥昔康家族,但它的特点是作为吡罗西康的前药,分子一旦溶解在消化道中就会发生水解转化。这使我们原则上可以假设,由于活性药物(吡罗昔康)与胃粘膜的接触较少,因此对胃粘膜的副作用很小。已经在健康志愿者和患有骨关节炎和类风湿性关节炎的患者中进行了研究,以评估droxicam对患有这种明显炎症过程的患者的疗效和耐受性。研究表明,在治疗两周后,droxicam具有明显的镇痛和抗炎作用,并且该药耐受性良好。
{"title":"Droxicam: a pharmacological and clinical review of a new NSAID.","authors":"F Jané,&nbsp;A Rodríguez de la Serna","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Droxicam acts by inhibition of PGE2 varies. Although it belongs to the oxicam family, it is characterised by being a pro-drug of piroxicam, the molecule undergoing conversion by hydrolysis once dissolved in the digestive tract. This allows us to suppose in principle that, there being less contact between the active drug (piroxicam) and the gastric mucosa, the side effects in the said mucosa would be slight. The studies which have already been performed in healthy volunteers and in patients with osteoarthritis and rheumatoid arthritis, to evaluate the efficacy and the tolerance of droxicam in patients suffering from such clearly inflammatory processes demonstrate an analgesic potential and anti-inflammatory effects which become noticeable after two weeks of treatment, and the drug is well-tolerated.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"11 4","pages":"3-9"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12539350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse events with droxicam in the early clinical trials. 在早期临床试验中的不良事件。
J Sánchez, A Bartlett, A Costa, J Estruch, R Estiarte, C Soucheiron

This study analyses the results of 8 randomized, controlled clinical trials and one open study carried out with droxicam (a new NSAID, pro-drug of piroxicam), comparing the adverse events and gastrointestinal tolerance of this compound against those of the control drugs used in these trials. The frequency of adverse events was lower in the droxicam treated patients. Adverse events concerning the gastrointestinal area were also lower. No differences were found in the distribution of adverse events by age of sex among the drugs compared. The pattern of side effects found was that expected in all non-steroidal anti-inflammatory agents. These results seem to sustain the hypothesis of a better tolerance of droxicam than that of piroxicam, indomethacin or diclofenac, especially in the gastrointestinal area.

本研究对droxicam(一种新型非甾体抗炎药,piroxicam的前药)进行的8项随机对照临床试验和1项开放研究的结果进行了分析,比较了该化合物与对照药物的不良事件和胃肠道耐受性。不良事件发生的频率较低。与胃肠道有关的不良事件也较低。不同药物间不良事件的年龄和性别分布没有差异。发现的副作用模式与所有非甾体抗炎药的预期相同。这些结果似乎支持了droxicam比piroxicam、吲哚美辛或双氯芬酸耐受性更好的假设,特别是在胃肠道区域。
{"title":"Adverse events with droxicam in the early clinical trials.","authors":"J Sánchez,&nbsp;A Bartlett,&nbsp;A Costa,&nbsp;J Estruch,&nbsp;R Estiarte,&nbsp;C Soucheiron","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This study analyses the results of 8 randomized, controlled clinical trials and one open study carried out with droxicam (a new NSAID, pro-drug of piroxicam), comparing the adverse events and gastrointestinal tolerance of this compound against those of the control drugs used in these trials. The frequency of adverse events was lower in the droxicam treated patients. Adverse events concerning the gastrointestinal area were also lower. No differences were found in the distribution of adverse events by age of sex among the drugs compared. The pattern of side effects found was that expected in all non-steroidal anti-inflammatory agents. These results seem to sustain the hypothesis of a better tolerance of droxicam than that of piroxicam, indomethacin or diclofenac, especially in the gastrointestinal area.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"11 4","pages":"50-8"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12539353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Variations between rheumatologists in using sulphasalazine. 风湿病学家使用磺胺嘧啶的差异。
D L Scott, J MacCarthy

The increased use of audit and resource management within the health service will focus attention on variations in clinical practice. We have looked at one rheumatological example; the extent rheumatologists vary in their clinical use of a slow-acting anti-inflammatory drug. We studied a single drug - sulphasalazine. In a prospective study sulphasalazine was given to 298 rheumatoid patients at 24 rheumatology centres in South East England. They were followed for 6 months. There were large differences between centres in: the types of patient started on therapy; the numbers of patients remaining on treatment; the responses after 6 months. The difference between some centres was more marked than the expected improvement in clinical and laboratory variables given by sulphasalazine. The use of a slow acting anti-rheumatic drug like sulphasalazine in rheumatoid arthritis is agreed by most rheumatologists in the UK and yet there are wide variations in its use. Our results question the validity of comparing clinical practice and associated costs between centres for even a simple clinical procedure.

在保健服务中更多地使用审计和资源管理将集中注意临床实践中的变化。我们已经看了一个风湿病的例子;风湿病学家在临床使用慢效消炎药的程度各不相同。我们研究了一种药物——磺胺嘧啶。在一项前瞻性研究中,在英格兰东南部的24个风湿病中心,298名类风湿患者服用了磺胺嘧啶。他们被跟踪了6个月。各中心之间的差异很大:开始接受治疗的患者类型;仍在接受治疗的患者人数;6个月后的反应。一些中心之间的差异比磺胺嘧啶给予的临床和实验室变量的预期改善更为显著。在英国,大多数风湿病学家都同意在类风湿性关节炎中使用像磺胺嘧啶这样的慢效抗风湿药物,但在使用方面存在很大差异。我们的结果质疑比较临床实践和中心之间的相关费用的有效性,即使是一个简单的临床程序。
{"title":"Variations between rheumatologists in using sulphasalazine.","authors":"D L Scott,&nbsp;J MacCarthy","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The increased use of audit and resource management within the health service will focus attention on variations in clinical practice. We have looked at one rheumatological example; the extent rheumatologists vary in their clinical use of a slow-acting anti-inflammatory drug. We studied a single drug - sulphasalazine. In a prospective study sulphasalazine was given to 298 rheumatoid patients at 24 rheumatology centres in South East England. They were followed for 6 months. There were large differences between centres in: the types of patient started on therapy; the numbers of patients remaining on treatment; the responses after 6 months. The difference between some centres was more marked than the expected improvement in clinical and laboratory variables given by sulphasalazine. The use of a slow acting anti-rheumatic drug like sulphasalazine in rheumatoid arthritis is agreed by most rheumatologists in the UK and yet there are wide variations in its use. Our results question the validity of comparing clinical practice and associated costs between centres for even a simple clinical procedure.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"11 2","pages":"46-52"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12538629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European journal of rheumatology and inflammation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1